Last updated: February 26, 2026
What is NDC 43598-0939?
NDC 43598-0939 is a drug marketed under the National Drug Code (NDC) identifier used for tracking and identification. The specific product corresponds to Rituximab (brand: Rituxan) as distributed by biologics manufacturers. Rituxan is a monoclonal antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune conditions.
Market Overview
1. Market Size and Key Drivers
The global rituximab market was valued at approximately USD 8.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 6.5% to reach USD 12.1 billion by 2030 [1].
Major drivers include:
- Increasing prevalence of hematological cancers and autoimmune diseases.
- Expansion of indications approved for rituximab.
- Growing use of biosimilar versions in regions with price-sensitive healthcare systems.
- Improvements in manufacturing efficiency reducing costs.
2. Geographic Market Breakdown
| Region |
Market Share (2022) |
CAGR (2023-2030) |
Key Factors |
| U.S. |
45% |
6.0% |
Patent expirations, biosimilar competition, pricing pressures |
| Europe |
25% |
7.0% |
Biosimilar adoption, healthcare funding |
| Asia-Pacific |
20% |
8.0% |
Increasing healthcare infrastructure, emerging middle class |
| Rest of World |
10% |
6.5% |
Regulatory development, market penetration |
3. Competitive Landscape
The market features:
- Innovator: Genentech/Roche's Rituxan.
- Biosimilars: Multiple entrants from companies like Sandoz, Samsung Bioepis, and Celltrion.
- Patent exclusivity for Rituxan expired around 2018 in the US and Europe, fostering biosimilar competition.
4. Regulatory Environment
- Biosimilars gaining approval globally, with US FDA approving Rituximab biosimilars starting in 2017.
- Pricing regulation varies; prices tend to be lower in regions with price controls, influencing revenue.
Price Projections
1. Current Pricing Trends
The average wholesale price (AWP) for a 100 mg vial of rituximab ranges from USD 2,500 to 3,500, depending on the region and manufacturer. Biosimilar versions are priced 15-40% below the innovator drug.
2. Projected Price Changes (2023-2030)
| Year |
Average Dose Price (USD per 100 mg vial) |
Notes |
| 2023 |
USD 2,700 |
Stable, slight reductions due to biosimilar competition |
| 2025 |
USD 2,300 |
Increased biosimilar penetration, price competition intensifies |
| 2030 |
USD 1,800 |
Expected price stabilization at lower levels, regulatory pressures |
The decline assumes increasing biosimilar market share and policy-driven price caps in select jurisdictions.
3. Market Penetration Impact on Price
- Biosimilar market share is projected to reach 40% in North America and 55% in Europe by 2030.
- Price reductions for biosimilars correlate with volume increases, but discounts may limit revenue growth of innovator brands.
Revenue and Sales Projections
| Year |
Estimated Global Sales (USD billions) |
Key Factors |
| 2023 |
USD 9.0 |
Post-pandemic recovery, biosimilar entry |
| 2025 |
USD 10.0 |
Market expansion, indication approvals |
| 2030 |
USD 12.1 |
Biosimilar proliferation, price stabilization |
Risks and Opportunities
Risks:
- Price erosion due to biosimilar competition.
- Regulatory delays or unfavorable pricing policies.
- Manufacturing or supply chain disruptions.
Opportunities:
- New indications increasing market size.
- Development of next-generation biosimilars.
- Regional market expansion.
Key Takeaways
- The global rituximab market is expected to grow at a CAGR of approximately 6.5%, reaching USD 12.1 billion by 2030.
- Price per 100 mg vial is projected to decline from USD 2,700 in 2023 to USD 1,800 in 2030, driven by biosimilar competition and regulatory price caps.
- Biosimilar penetration will significantly influence pricing and market share in North America and Europe.
- The primary revenue growth will stem from expanding indications and regional market expansion, especially in emerging markets.
FAQs
1. How competitive is the biosimilar market for rituximab?
Biosimilar market share is expected to grow to around 40% globally by 2030. Multiple biosimilar products are approved and captured significant market volume, exerting downward pressure on prices.
2. What are the key regulatory factors affecting pricing?
Regulatory approval for biosimilars at reduced costs, pricing policies in different countries, and patent expirations influence overall market prices.
3. How will indications expanded beyond oncology affect the market?
New indications, such as autoimmune diseases, are expected to increase the total addressable market, contributing to revenue growth despite price reductions.
4. What regional trends influence pricing strategies?
Regions with price regulations or healthcare budget constraints—such as Europe and parts of Asia—tend to see steeper price declines for biosimilars.
5. What is the impact of supply chain issues on the market?
Disruptions can hinder availability, potentially increasing prices temporarily but generally not altering long-term market dynamics significantly.
References
[1] Grand View Research. (2023). Rituximab Market Size, Share & Trends Analysis Report.
